Your company’s employer brand is your reputation as an employer and is crucial in attracting top talent. Some reputations are just not good; they may or not be deserved. That is just the perception in the market. Years ago there…
Japan’s health ministry approved a batch of medicines for broader labels on February 9 including Nippon Boehringer Ingelheim’s SGLT2 inhibitor Jardiance (empagliflozin) for the treatment of chronic kidney disease (CKD). Jardiance has been available in Japan for the indication of…
To read the full story
Related Article
- Opdivo, Olumiant, Dupixent Now in Line for Label Expansions
February 6, 2024
- Jardiance’s CKD Indication in Line for Japan Approval with Key Panel Nod
January 29, 2024
REGULATORY
- NCC President Nakagama to Lead AMED from April
March 26, 2025
- Pariet’s Nonprescription Versions Approved 6 Years after Discussions Start
March 25, 2025
- AMED President Mishima Hints at Resignation
March 25, 2025
- FPMAJ Prods Drastic Review of Fiscal Framework before Honebuto 2025
March 25, 2025
- Difficult to “Visualize” Distribution, Production Costs in NHI Prices: Minister
March 25, 2025
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…